Cansortium Inc., a vertically integrated, multi-state cannabis company operating under the FLUENT brand, today announced the launch of Bag-O, a new value-focused line of premium cannabis flower, available to Florida medical marijuana patients starting today, January 7.

“With an emphasis on quality and affordability, Bag-O offers patients access to cannabis at competitive prices, expanding FLUENT’s product offerings and reinforcing its commitment to accessibility”, states a press release.

“Bag-O was developed in direct response to patient feedback, addressing the growing demand for larger quantities of high-quality cannabis at an affordable price point,” said Robert Beasley, CEO of FLUENT. “Thanks to our vertically integrated operations, we maintain strict quality control throughout the entire process—from cultivation to packaging—ensuring that our patients receive premium cannabis in larger quantities without the premium price tag. We’re proud to meet this demand and look forward to expanding Bag-O to new markets.”
Continue reading

The global cannabis testing services market is projected to expand from $2.5 billion in 2024 to over $12 billion by 2034, reflecting a robust compound annual growth rate (CAGR) of 17.26%.

This growth is fueled by the increasing legalization of cannabis worldwide, heightened awareness of safety and quality standards, and advancements in testing technologies, according to a new Research and Markets report.

Legalization for medical and recreational cannabis in regions such as the United States, Canada, and parts of Europe and Asia has led to a surge in demand for comprehensive testing services, notes the report. Currently, 39 U.S. states allow medical marijuana, with 24 states also legalizing recreational use. These changes underscore the importance of reliable testing to meet evolving regulatory requirements.

Among testing services, potency testing leads in revenue generation, driven by the need to accurately measure THC and CBD levels for compliance and consumer safety. Innovations like the Trust in Testing Certification, introduced by ACT Laboratories and SC Labs, highlight the industry’s push for standardized testing protocols. Meanwhile, flower testing dominates sample types due to its prevalence in the market, with extracts showing the fastest growth, thanks to their use in edibles and concentrates.

Regionally, North America commands the largest market share due to established testing labs and stringent regulations. The Asia Pacific region, however, is expected to grow at the fastest rate, spurred by the adoption of medical cannabis in countries like Thailand and Japan.

As cannabis legalization continues to spread, the industry’s focus on rigorous testing will remain essential to ensure product quality, consumer safety, and regulatory compliance. For more information on this report, click here.

The global hemp-derived cannabidiol market size was estimated to be $8.28 billion at the end of 2023, growing to nearly $10 billion to end 2024, according to a new report.

The report by Research and Markets found that the global CBD market is expected to reach $46.25 billion by 2034 with a compound annual growth rate (CAGR) of 16.93% during the forecast period 2024-2034.

“Growing demand for CBD in personal care and cosmetics, shifting consumer acceptance of CBD, hemp legalization, regulatory changes, increased R&D, and a shift toward natural and plant-based wellness products will all contribute to the market’s growth”, notes the report. “The global shift towards natural, plant-based products is driving an increasing demand for CBD, which is recognized as a natural alternative to traditional pharmaceuticals for alleviating pain, stress, and inflammation.”
Continue reading